8-K: VSee Health Secures $133K Debt Financing

VSee Health, Inc. has secured a $133,333.33 senior secured promissory note from Ascent Partners Fund LLC for working capital, maturing in May 2026.

Summary

• VSee Health, Inc. (the Company) entered into a Note Purchase Agreement with Ascent Partners Fund LLC on October 20, 2025.
• The Company issued a Senior Secured Promissory Note with a principal amount of $133,333.33 for a purchase price of $120,000.00.
• The Note bears interest at 5% per annum and matures on May 20, 2026.
• Proceeds from the Note will be used for the Company's working capital.
• The Note is secured by the assets of the Company and its subsidiaries, VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc., through amendments to existing security agreements and guaranties.
• The Company terminated an Equity Purchase Agreement with Dominion Capital LLC on October 18, 2025.

Sentiment

Score: 5

Explanation: The financing provides essential working capital, which is positive for operations. However, the terms are quite restrictive, including a significant original issue discount, a high default interest rate, and limitations on future capital-raising activities, indicating a higher risk profile and potentially challenging financing environment for the Company.

Positives

• Secured $120,000 in immediate funding for working capital.
• The debt is secured by company assets, potentially offering stability to the lender and indicating asset backing.
• The interest rate of 5% per annum is reasonable for secured debt.

Negatives

• The purchase price of $120,000 for a $133,333.33 principal amount implies an original issue discount (OID) of $13,333.33, increasing the effective cost of borrowing.
• A high default interest rate of 24% per annum applies immediately upon an Event of Default, indicating significant risk for the Company if it fails to meet obligations.
• The Company is subject to mandatory prepayment of 100% of net proceeds from any future capital-raising transactions, which could limit flexibility in future financing.
• Prohibitions on variable-priced equity-linked instruments and exchange transactions restrict future financing options and capital structure management.
• The "most favored nation" clause requires the Company to offer any more favorable terms granted to future debt/securities holders to the current investor, potentially limiting future negotiation leverage.
• Failure to maintain current public information requirements under Rule 144(c) incurs liquidated damages of 2.0% of the Note's principal amount every 30 days.

Risks

• Default Risk: Numerous events of default, including payment defaults, breaches of covenants, untrue representations, bankruptcy, significant judgments ($250,000+), and trading market issues (e.g., becoming penny stock, delisting, DTC chill).
• Liquidity Risk: Mandatory prepayment from future capital raises could force the Company to use new funds to repay this debt, potentially hindering growth initiatives or other operational needs.
• Financing Flexibility Risk: Restrictions on variable-priced equity-linked instruments and exchange transactions limit the Company's ability to raise capital or restructure debt in the future, especially in challenging market conditions.
• Compliance Risk: Failure to comply with SEC reporting and public information requirements (Rule 144(c)) will result in financial penalties (liquidated damages).
• Operational Restrictions: Negative covenants restrict the Company's ability to incur additional debt, create liens, sell assets outside the ordinary course, amend charter documents, make restricted payments, or engage in certain related-party transactions, potentially limiting strategic flexibility.
• Market Risk: Events of default include the Common Stock becoming penny stock, losing its trading market, or having its transfer through DTC chilled, which could severely impact shareholder value and the Company's ability to raise capital.

Future Outlook

The Company intends to use the proceeds from this financing for working capital, supporting ongoing operations. However, future capital-raising efforts will be subject to mandatory prepayment obligations for this note and restrictions on certain types of equity-linked instruments and exchange transactions.

Management Comments

• Imoigele Aisiku, Co-Chief Executive Officer, signed the 8-K filing on behalf of VSee Health, Inc.
• Milton Chen, Chief Executive Officer, signed the Amendment Agreement on behalf of VSee Lab, Inc.
• Imoigele Aisiku, Chief Executive Officer, signed the Amendment Agreement on behalf of iDoc Virtual Telehealth Solutions, Inc.

Industry Context

VSee Health operates in the telehealth and virtual healthcare solutions industry. This debt financing provides necessary working capital, which is common for growth-stage companies in technology-driven healthcare sectors that often require continuous investment in R&D, market expansion, and operational infrastructure. The termination of a previous equity line of credit suggests a shift in financing strategy or a response to market conditions, potentially indicating a preference for secured debt over further equity dilution at this time, or an inability to continue with the ELOC terms.

Comparison to Industry Standards

• The 5% interest rate for secured debt is generally within a reasonable range for companies with established operations but may be higher than for larger, more stable industry players.
• The 24% default interest rate is significantly high, reflecting a substantial risk premium for the lender in case of non-compliance, which is common in distressed or high-risk debt financing but can be punitive.
• The original issue discount (OID) of approximately 10% ($13,333.33 on $133,333.33 principal) is a notable cost of capital, indicating that the Company might not have been able to secure financing at par.
• The restrictive covenants, including mandatory prepayment from future offerings and prohibitions on variable-priced equity-linked instruments, are more stringent than typically seen in mature, investment-grade companies, suggesting the Company's need for capital and the lender's desire for strong protections.
• The termination of an Equity Line of Credit (ELOC) could be viewed negatively if it implies a lack of investor confidence in the Company's equity or an inability to meet prior ELOC terms, contrasting with companies that successfully leverage such facilities for flexible capital.

Corporate Governance

Related Party Transactions

• Ascent Partners Fund LLC is the investor for the new Senior Secured Promissory Note and also acts as the Collateral Agent.
• Dominion Capital LLC is a party to previous security agreements and guaranties that were amended to include the new note. The Company also terminated an Equity Purchase Agreement with Dominion Capital LLC.

Stakeholder Impact

• Shareholders: Potential for future dilution if the mandatory prepayment clause forces the Company to raise equity to repay this debt. The restrictive covenants on future financing could also limit growth opportunities.
• Employees: The use of proceeds for working capital can help ensure continued operations and stability, which is positive for employees.
• Creditors (Ascent Partners Fund LLC): The Note is senior secured and benefits from a "most favored nation" clause and broad indemnification, placing Ascent in a strong position.
• Creditors (Dominion Capital LLC): Their existing security agreements and guaranties were amended to include the new note, potentially affecting their relative position or the overall collateral pool.
• Customers/Suppliers: Stable working capital can ensure continuity of services and payments, which is positive for customers and suppliers.

Next Steps

• The Company must ensure timely filing of all required reports under the Exchange Act.
• The Company must maintain compliance with Rule 144(c) public information requirements to avoid liquidated damages.
• The Company must adhere to all negative covenants, including restrictions on future indebtedness, liens, asset sales, and certain capital structure changes.
• The Company must use the proceeds for working capital as stipulated in the Purchase Agreement.

Key Dates

Recommendation

The Company has successfully secured crucial working capital through this debt financing, which is a positive for its immediate operational stability. However, the terms of the note are quite restrictive, including a significant original issue discount, a high default interest rate, and stringent covenants that limit future financing flexibility and capital structure management. The mandatory prepayment clause tied to future capital raises could lead to further equity dilution for existing shareholders. While the financing addresses an immediate need, the long-term implications of these restrictive terms and the high cost of capital warrant a cautious 'hold' recommendation. Investors should monitor the Company's ability to meet its obligations, manage its capital structure under these constraints, and its overall financial performance.

Keywords

VSee Health, Debt Financing, Promissory Note, Secured Debt, Working Capital, Ascent Partners Fund, SEC Filing, 8-K, Corporate Finance, Risk Management, Capital Raise, Telehealth